HOME >> BIOLOGY >> NEWS
IMS updated recommendations on postmenopausal hormone therapy

INTRODUCTION

The past decade has seen marked fluctuations in opinions concerning the merits and risks of postmenopausal hormone therapy. In July 2002, menopause management faced a major turning point when the first data from the Womens Health Initiative (WHI) trial were released. The study was categorized as a primary prevention trial for coronary heart disease, although the fact that mean age at recruitment was 63 years was not given enough importance at that time. WHI investigators concluded that hormone therapy (HT) was not cardioprotective, and, in fact, its riskbenefit ratio did not favor the use of postmenopausal hormones for prevention of chronic diseases. As a result, there was a dramatic change in prescription habits following recommendations to reserve HT for very symptomatic women, and to limit its use to the shortest duration needed and to the lowest effective dosage. This was the atmosphere in which the International Menopause Society (IMS) initiated the IMS Workshop held in Vienna (December 2003) and the IMS Position Paper that was based on the Workshop discussions. Looking at global perspectives, and being independent of local or regional constraints imposed by official health authorities, this IMS Statement called for a more balanced approach in the interpretation of the scientific data on hormone use that were available in 2003. Since then, additional information has been accumulated from both arms of the WHI study, observational trials and from other studies, allowing a more comprehensive review on all issues related to the use of hormones in the postmenopausal period. In view of the above, the IMS Board decided that it is time to update the 2004 Statement and to enlarge its scope to menopause management and adult womens health in general. More than 30 experts from the various fields of menopause medicine reviewed the latest information in a Workshop held in Budapest in February 2007.

The following Recommendations exp
'"/>

Contact: Jean Wright
jwright.ims@btopenworld.com
International Menopause Society
16-May-2007


Page: 1 2 3 4 5 6 7

Related biology news :

1. Mitochondrial DNA sequencing tool updated
2. Rutgers College of Nursing Deans award winning book updated and released
3. Penn researchers provide recommendations for artificial nutrition and hydration
4. 9/11 panel makes recommendations for DNA-based identification after mass disasters
5. New report offers recommendations to spur interdisciplinary research
6. Study finds Western-style meat-sweet diet increases risk of breast cancer in postmenopausal women
7. Gum disease in postmenopausal women linked to oral bone loss
8. Raloxifene reduces breast cancer risk in postmenopausal women at all risk levels
9. Circadian clock controls plant growth hormone
10. Role of thyroid hormones in slumber under investigation at Rutgers
11. Breast cancer and hormone therapy -- A looking-glass mirror?

Post Your Comments:
(Date:6/17/2013)... by fungi, bacteria, and algae, is a common component ... used in the medical field it,s approved by ... fluids and used during surgery as a substance that ... other drugs. , Now Profs. Ehud Gazit and Daniel ... and Biotechnology and the Sagol School of Neuroscience, along ...
(Date:6/17/2013)... will be the topics under discussion during the ... the third consecutive year, this will be a ... experiences among members of Academy, Business, Educators, Entrepreneurs, ... speakers: Elisa Martn Garijo (IBM South Europe), Chris ... Mary O,Donovan (Hovione), among others. E3 Forum - ...
(Date:6/17/2013)... available in French . ... older mice with Alzheimer,s disease can be reversed with treatment. ... Hospital - The Neuro, at McGill University and at Universit ... receptor in the brain of mice with advanced Alzheimer,s disease ... the Journal of Neuroinflammation in May, also suggest ...
Breaking Biology News(10 mins):Artificial sweetener a potential treatment for Parkinson's disease 2'E3 Forum -- Education, Employment & Entrepreneurship on a Global context' 2Blocking overactive receptor in Alzheimer's recovers memory loss and more 2
(Date:6/14/2013)... 2013  Royalty Pharma notes today,s announcement by Elan Corporation, ... explore a sale of the Company. Royalty Pharma believes it ... certainty that a deal will ever be reached. Royalty Pharma calls ... AGAINST all four resolutions up for consideration at Elan,s EGM ... formal offer for Elan. In response to the announcement ...
(Date:6/14/2013)... June 14, 2013 The OpenClinica ... Hotel, Boston, MA this year with Formedix CEO, Mark ... valuable sessions, offering attendees a deeper insight into the ... with partners, such as Formedix to develop innovative solutions. ... to learn all about OpenClinica, hear real-life case studies ...
(Date:6/14/2013)... June 14, 2013 The Pittcon Exposition ... 2014, which will be held March 3-6, 2014, at ... Chicago, Illinois. The cost per booth after July 15, ... the first round of booth assignments should have their ... placements will begin August 2013. , Pittcon attracts a ...
(Date:6/14/2013)...  The Pittsburgh Life Sciences Greenhouse (PLSG) today announced ... were necessitated by delays in portfolio company exits caused ... of state funding. PLSG President and CEO, ... only pure life sciences investment firm, the actions taken ... of Directors, were necessary to protect the future of ...
Breaking Biology Technology:Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 2Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 3Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 4Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 5Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 6Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 7Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 8Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 9Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 10Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 11Formedix CEO Invited to Speak at OpenClinica Global Conference in Boston 2Formedix CEO Invited to Speak at OpenClinica Global Conference in Boston 3Pittcon 2014 Now Accepting Booth Space Reservations 2Pittsburgh Life Sciences Greenhouse Makes Significant Reductions Due to Uncertain Funding 2
Cached News: